Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $22.6 billion in annual brand sales, for the 12 months ending Dec. 31, 2012, according to IMS Health.This press release includes statements that constitute forward-looking statements, including with regard to the expected first-to-file status and pending litigation.